Dexcom (NASDAQ: DXCM) CFO has 1,451 RSU shares withheld for taxes

Rhea-AI Filing Summary

Dexcom EVP and Chief Financial Officer Sylvain Jereme M reported a routine tax-related share withholding. On May 22, 2026, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations tied to restricted stock unit settlement, and the footnote clarifies this does not represent a sale.

After this withholding, he directly holds 151,841 shares of common stock, which includes 89,944 unvested restricted stock units. These RSUs were granted in multiple awards between March 8, 2024 and March 8, 2026 and are scheduled to vest through March 8, 2029, indicating a significant ongoing equity-based compensation position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sylvain Jereme M

Role EVP, Chief Financal Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,451	$71.90	$104K

Holdings After Transaction: Common Stock — 151,841 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. Included in this number are 89,944 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares withheld for taxes: 1,451 shares Withholding price per share: $71.90 per share Shares held after transaction: 151,841 shares +5 more

8 metrics

Shares withheld for taxes 1,451 shares Tax withholding on RSU net settlement on May 22, 2026

Withholding price per share $71.90 per share Value used for tax-withholding shares on May 22, 2026

Shares held after transaction 151,841 shares Direct Dexcom common stock ownership following withholding

Unvested RSUs total 89,944 RSUs Included within total shares held after transaction

RSUs granted March 8, 2026 48,774 RSUs Unvested; scheduled to vest through March 8, 2029

RSUs granted March 8, 2025 (2028 vest) 23,937 RSUs Unvested; scheduled to vest through March 8, 2028

RSUs granted March 8, 2025 (2027 vest) 8,549 RSUs Unvested; scheduled to vest through March 8, 2027

RSUs granted March 8, 2024 8,684 RSUs Unvested; scheduled to vest through March 8, 2027

Key Terms

restricted stock units, net settlement, tax withholding, unvested restricted stock units

4 terms

restricted stock units financial

"in connection with the net settlement of restricted stock units and does not represent a sale"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units"

tax withholding financial

"required to be withheld by the Issuer to cover tax withholding and remittance obligations"

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

unvested restricted stock units financial

"Included in this number are 89,944 unvested restricted stock units, 48,774 of which were granted"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sylvain Jereme M

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		F		1,451(1)	D	$71.9	151,841(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

2. Included in this number are 89,944 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Dexcom (DXCM) CFO Sylvain Jereme M report in this Form 4?

Dexcom CFO Sylvain Jereme M reported that 1,451 shares of common stock were withheld to cover tax obligations from restricted stock unit settlement. This is a tax-withholding disposition, not an open-market sale, and reflects routine handling of equity compensation taxes.

Was the Dexcom (DXCM) CFO’s Form 4 transaction a stock sale?

No, the filing explicitly states the 1,451 shares represent shares withheld by Dexcom to cover tax withholding and remittance obligations. The footnote clarifies this withholding in connection with net settlement of restricted stock units does not represent a sale by the reporting person.

How many Dexcom (DXCM) shares does the CFO hold after this transaction?

Following the tax withholding, the CFO directly owns 151,841 Dexcom common shares. This total includes both vested shares and 89,944 unvested restricted stock units that are scheduled to vest over several years, providing substantial ongoing equity exposure.

What restricted stock units does the Dexcom (DXCM) CFO have outstanding?

The CFO has 89,944 unvested restricted stock units outstanding. These include awards granted on March 8, 2026, March 8, 2025, and March 8, 2024, with scheduled vesting dates extending through March 8, 2029 under Dexcom’s equity compensation program.

Over what period will the Dexcom (DXCM) CFO’s RSUs vest?

The unvested restricted stock units held by the CFO vest over several years, with tranches scheduled to vest through March 8, 2027 and March 8, 2029. This staggered vesting structure aligns long-term incentive compensation with Dexcom’s multi-year performance horizon.